• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [24125 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2015     Haute Autorite de sante (HAS) [Gene amplification to detect herpes simplex virus (HSV) and varicella-zoster virus (VZV) genomes in cerebrospinal fluid in cases of encephalitis]
2021     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Gender-specific differences in drug effects. Exemplary analysis based on beta-adrenoceptor antagonists as cardiac therapy and antidepressants as psychotropic drugs]
2000     Andalusian Health Technology Assessment Area (AETSA) [Gender dysphoria: possible interventions and coverage in Andalusian Health System - systematic review, economic evaluation]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gemtuzumab ozogamicin (acute myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2010     Institute for Clinical Effectiveness and Health Policy (IECS) [Gefitinib for the treatment of lung cancer]
2008     Committee for New Health Technology Assessment (CNHTA) [GBA gene, mutation[sequencing]]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Gated-SPECT in ischemic non-obstructive coronary artery disease (microvascular angina - INOCA)]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Gastrointestinal bleeding control using endoscopic hemostatic powder]
2008     Committee for New Health Technology Assessment (CNHTA) [Gastric cancer sentinel node excision]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Garadacimab (hereditary angioedema) – Benefit assessment according to §35a Social Code Book V]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Gamma Knife versus adapted linear accelerators: A comparison of two radiosurgical applications]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Galsulfase (Naglazyme) for the treatment of mucopolysaccharidosis type VI]
2010     Committee for New Health Technology Assessment (CNHTA) [GALK1 gene mutation analysis[sequencing]]
2010     Committee for New Health Technology Assessment (CNHTA) [GALE gene,mutation[sequencing]]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Galcanezumab (migraine) - Second Addendum to Commission A19-28]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Galcanezumab (migraine) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Galcanezumab (migraine) - Addendum to commission A19-28]
2019     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Gait speed as predictor of frailty]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Gait laboratory in patients with gait disorders]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Gadoxetic acid-enhanced magnetic resonance imaging to diagnose focal liver lesions]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gadopiclenol (contrast-enhanced magnetic resonance imaging) – Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gabapentin: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2008     Committee for New Health Technology Assessment (CNHTA) [GAA gene, mutation[sequencing]]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Futibatinib (cholangiocarcinoma) – Benefit assessment according to § 35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Futibatinib (cholangiocarcinoma) – addendum to Project A24-66]
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Functioning and disability - an evidence map]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Functional dysphagia therapy up to 5 weeks after oncological therapy: Evidence report for the S3 guideline „Oropharyngeal dysphagia“ due to head and neck tumours – diagnosis and treatment]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Functional dysphagia therapy at least 6 weeks after oncological therapy: Evidence report for the S3 guideline „Oropharyngeal dysphagia“ due to head and neck tumours – diagnosis and treatment]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Fulvestrant for the treatment of locally advanced ormetastatic breast cancer]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Fully bioresorbable scaffolds for coronary artery disease: systematic review]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Fully bioresorbable drug-eluting coronary scaffolds: A review]
2025     Canary Health Service [FT-Raman spectroscopy with data analysis using machine learning for the diagnosis of platinum-resistant ovarian cancer]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fruquintinib (colorectal cancer) – Benefit assessment according to §35a Social Code Book V]
2001     Finnish Office for Health Care Technology Assessment (Finohta) [From traditional film-based radiology to digital imaging: a simplified model for costing radiology services in small and medium-sized radiology units]
1999     Finnish Office for Health Care Technology Assessment (Finohta) [From science to practice - systematic reviews in health care]
2003     The Netherlands Organisation for Health Research and Development (ZonMw) [From efficacy to effectiveness in cancer research]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fremanezumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fremanezumab (migraine) - Addendum to Commission A19-44]
2005     Andalusian Health Technology Assessment Area (AETSA) [Framework for the assessment of genetic testing in the Andalusian public health system]
2021     Canary Health Service [Framework for relations between the Spanish Network of HTA agencies of the NHS with industry]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fracture sonography in children with suspected fracture of a long tubular bone of the upper extremities]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Fractional flow-reserve by intracoronary pressure guidewire in patients with acute coronary syndrome]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Fractional flow reserve in coronary artery]
2015     Haute Autorite de sante (HAS) [Fractional flow reserve (FFR) measurement during coronary angiography]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Fractional exhaled nitric oxide measurement in patients with asthma and chronic cough]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fostemsavir (HIV infection) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fostamatinib (chronic immune thrombocytopenia) - Benefit assessment according to §35a Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fosdenopterin (molybdenum cofactor deficiency Type A) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Food in diabetes]
2007     Health Council of the Netherlands Gezondheidsraad (GR) [Food allergy]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Food allergen-specific IgG4 (immunoglobulin G4) measurement by immunoassay]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [FONAKIDs® multimodal approach in congenital or acquired apraxia of speech]
2007     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Follow-up visits from nurses after discharge from multidisciplinary pain centre - a health technology assessment]
2009     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Follow-up in gynaecological cancer patients - a health technology assessment]
2009     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Follow-Up for gynecological cancer]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Foetal growth retardation at term: induction of labour or not? A comparison of maternal and neonatal outcome, maternal quality of life and costs (DIGITAT). The Disproportionate Intrauterine Growth Intervention Trial At Term (DIGITAT)]
2023     HTA South [Focused ultrasound treatment for tremor]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [FOAM-study. Cost minimization study comparing surgery versus duplex guided foam sclerotherapy of varicose veins: a randomized controlled study]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Addendum to Commission A18-79]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fluticasone furoate/umeclidinium/vilanterol (COPD) - Addendum to Commission A18-15]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Fluorodopa PET scanning in Parkinson’s disease]
2010     Finnish Office for Health Care Technology Assessment (Finohta) [Fluorescence cystoscopy in diagnosis and management of superficial bladder cancer]
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Flashglucose monitoring system (Freestyle Libre, Abbott), report updated April 8 2020]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Flash glucose monitoring system in diabetes mellitus patients]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Flash glucose monitoring system in diabetes mellitus patients]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Flash glucose monitoring system in diabetes mellitus patients]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fixed combinations of corticosteroids and long-acting beta-2-receptor agonists for inhaled use in patients with asthma]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fixed combinations of corticosteroids and long-acting beta-2-receptor agonists for inhaled use in patients with asthma - supplementary commission]
2015     Norwegian Knowledge Centre for the Health Services (NOKC) [First aid training may improve first aid skills]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Fingolimod for relapsing/remitting multiple sclerosis (RRMS)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (new therapeutic indication) - Addendum to Commission A15-48]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod (multiple sclerosis in children and adolescents) - Addendum to Commission A18-87]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fingolimod - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 3 and 4) – Addendum to Commission A23-15]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 2 and 3) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 1 and 2) – Addendum to Commission A23-14]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Finerenone (CKD stage 1 and 2) - Benefit assessment according to §35a Social Code Book V]
2011     Basque Office for Health Technology Assessment (OSTEBA) [Financing procedures in primary care adequate for resources and efficiency, by means of adjusted clinical groups (ACG)]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [FilmArray® in Acute Respiratory Infections and Sepsis]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Filgotinib (ulcerative colitis) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Filgotinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V]
2014     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Field evaluation of the initial treatment of STEMI in Quebec's hospitals - phase 2]
2020     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Field evaluation of the implementation of video teleconsultations during the COVID-19 pandemic at the Quebec Heart and Lung Institute]
2013     Andalusian Health Technology Assessment Area (AETSA) [Fidaxomicin for the treatment of clostridium difficile infection]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fidaxomicin (clostridioides difficile infection) - Benefit assessment according to §35a Social Code Book V]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fidaxomicin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fidanacogene elaparvovec (haemophilia B); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Fibromyalgia and chronic fatigue syndrome: recommendations on diagnosis and treatment]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fibromatoses of the hand (Dupuytren's disease) and / or foot (Ledderhose's disease): do those affected benefit from radiation therapy?]
2025     Institut national d'excellence en sante et en services sociaux (INESSS) [Fibrin sealants and hemostatic matrices in an intraoperative context]
2010     Committee for New Health Technology Assessment (CNHTA) [Fiberoptic endoscopic evaluation of swallowing]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fezolinetant (vasomotor symptoms in menopause) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fezolinetant (vasomotor symptoms in menopause) – Addendum to Project A24-15]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Fetoscopic laser photocoagulation in twin-twin transfusion syndrome]